Barclays Capital Reaffirms Equalweight Rating on Par Pharmaceutical Companies Incorporated (PRX)

By admin | 6 years ago

Par Pharmaceutical Companies Incorporated (NYSE: PRX)‘s stock had its “equalweight” rating restated by equities researchers at Barclays Capital (NYSE: BCS) in a report issued on Thursday.

Shares of Par Pharmaceutical Companies Incorporated opened at 35.84 on Thursday. Par Pharmaceutical Companies Incorporated has a one year low of $24.85 and a one year high of $42.25. The company has a market cap of $1.305 billion and a P/E ratio of 23.94.

Par Pharmaceutical Companies Incorporated last issued its quarterly earnings data on Tuesday, May 8th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.08. The company’s revenue for the quarter was up 16.5% on a year-over-year basis. On average, analysts predict that Par Pharmaceutical Companies Incorporated will post $1.07 earnings per share next quarter.

A number of other analysts have also recently weighed in on PRX. Analysts at Needham & Company reiterated a “strong-buy” rating on shares of Par Pharmaceutical Companies Incorporated in a research note to investors on Wednesday. Separately, analysts at UBS AG (NYSE: UBS) raised their price target on shares of Par Pharmaceutical Companies Incorporated from $42.00 to $48.00 in a research note to investors on Wednesday, May 9th. They now have a “buy” rating on the stock.

Par Pharmaceutical Companies, Inc., is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc.

About the author